Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02989025 · ClinicalTrials.gov registry record · Phase 2
Progesterone to Enhance the Efficacy and Success of Expectantly Managed Preterm Severe/Superimposed Preeclampsia
A Phase 2 study of Pregnancy and Preeclampsia (PE), sponsored by University of Mississippi Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT02989025: Recruiting Phase 2 study of Pregnancy and Preeclampsia (PE), sponsored by University of Mississippi Medical Center.
NCT02989025 is a Phase 2 study of Pregnancy and Preeclampsia (PE) that is actively recruiting participants, run by University of Mississippi Medical Center. The registered enrollment target is 60 participants, below the 872-participant average among 191 other Pregnancy trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02989025, a Phase 2 study of Pregnancy and Preeclampsia (PE), is actively recruiting participants, sponsored by University of Mississippi Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to learn if giving 17-hydroxyprogesterone caproate (17 OHPC) to mothers with preeclampsia diagnosed before 34 weeks gestation improves mother and baby outcomes.
Primary Outcome
Assessment of maternal BP trends
Conditions Studied
Interventions
- DRUG 17 OHPC
Study Locations (1)
Mississippi
- Winfred L. Wiser Hospital - Jackson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2017-05-22 |
| Est. Completion | 2027-01-31 |
| Phase | Phase 2 |
What NCT02989025 shows while recruiting
NCT02989025 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 872-participant average among 191 other Pregnancy trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with Pregnancy appearing as the primary indexed condition, and to 1 intervention - of which 17 OHPC is the first listed.
NCT02989025 reports a single indexed study location in Mississippi.
Frequently Asked Questions
What is clinical trial NCT02989025 about?
NCT02989025 is a clinical study titled "Progesterone to Enhance the Efficacy and Success of Expectantly Managed Preterm Severe/Superimposed Preeclampsia". The purpose of this study is to learn if giving 17-hydroxyprogesterone caproate (17 OHPC) to mothers with preeclampsia diagnosed before 34 weeks gestation improves mother and baby outcomes.
What is the current status of trial NCT02989025?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2017-05-22. Estimated completion is 2027-01-31.
What conditions does trial NCT02989025 study?
This clinical trial studies the following conditions: Pregnancy, Preeclampsia (PE).
What interventions are being tested in trial NCT02989025?
The interventions under investigation include: 17 OHPC (DRUG).
Who is sponsoring clinical trial NCT02989025?
This trial is sponsored by University of Mississippi Medical Center, which has 96 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02989025 being conducted?
This trial has 1 study location across Mississippi. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pregnancy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02989025's enrollment target sits among peer trials
60 144th of 191 higher than 43 of 191 other Pregnancy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pregnancy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Pharmacology of 17-OHPC in Pregnancy
COMPLETED · Phase 2
-
Healthy4Baby: Preventing Postpartum Weight Retention Among Low-Income, Black Women
COMPLETED · Phase 2
-
Intravaneous Iron(1000 mg Low Molecular Weight Iron Dextran Over 60 Minutes) for Pregnant Women
COMPLETED · Phase 2
-
Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
RECRUITING
-
CGM Adherence Compared to Finger-stick Glucose Monitoring in Pregnancies With Type 2 Pregestational Diabetes
RECRUITING · NA
-
Healthy Start: Exploring the Fuel-mediated Programming of Neonatal Growth
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI